.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Dr. Lisa Oestereich

Hamburg/ DE

Bernhard-Nocht-Institut für Tropenmedizin

Speaker

26/09/2023
Poster
P-2-86
Reporter-virus-based screening for novel anti-Lassa virus drugs
Tropical and Emerging Infections

Further involvements

26/09/2023
Poster
P-2-86
Reporter-virus-based screening for novel anti-Lassa virus drugs
Tropical and Emerging Infections
26/09/2023
Poster
P-2-95
A novel SARS-CoV-2 replicon system expressing a secreted luciferase and the GFP-zeocin fusion protein
Tropical and Emerging Infections
26/09/2023
Poster
P-2-100
Clinical performance evaluation of a real-time PCR kit for the detection of Lassa virus
Tropical and Emerging Infections
26/09/2023
Poster
P-2-102
System serology in Lassa fever survivors from Edo State, Nigeria
Tropical and Emerging Infections
26/09/2023
Poster
P-2-109
Follow-up of survivors of Lassa Fever in Edo State, Nigeria: studies of correlates of immunity
Tropical and Emerging Infections
26/09/2023
15:40 – 15:50 8 Min. 2 Min.
Short Talk
S-6-5
A randomized controlled phase II clinical trial assessing pharmacokinetics of favipiravir for the treatment of Lassa fever
Tropical and Emerging Infections